Cargando…
Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan
PURPOSE: The optimal treatment following endocrine therapy (ET) plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) has not been established. We aimed to investigate treatment patterns and time to treatment failure (TTF) of subsequent therapy after palbociclib in a Japanese real-world setting. ME...
Autores principales: | Sawaki, Masataka, Muramatsu, Yasuaki, Togo, Kanae, Iwata, Hiroji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248381/ https://www.ncbi.nlm.nih.gov/pubmed/37267715 http://dx.doi.org/10.1016/j.breast.2023.05.006 |
Ejemplares similares
-
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2019) -
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
por: Masuda, Norikazu, et al.
Publicado: (2020) -
Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
por: Takahashi, Masato, et al.
Publicado: (2020) -
Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study
por: Masuda, Norikazu, et al.
Publicado: (2018) -
Practice management for elderly patients with
breast cancer; Findings from a survey by the Japan Breast Cancer Study
Group
por: Sawaki, Masataka, et al.
Publicado: (2018)